Desmopressin vs Vasopressin
How they differ
- FDA status, the same for both (FDA-approved). Desmopressin: FDA-approved as DDAVP for diabetes insipidus and bedwetting.1,2 Vasopressin: FDA-approved as Vasostrict for vasodilatory shock.3,4
- Kinds of studies cited. Desmopressin: smaller controlled human trials. Vasopressin: limited human data. How these labels are assigned
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Desmopressin | Vasopressin |
|---|---|---|
| What it is | A synthetic analogue of the pituitary hormone arginine vasopressin with stronger antidiuretic and weaker blood-pressure effects, according to the DDAVP label.1 | A synthetic polypeptide hormone, arginine vasopressin, that acts on V1 receptors in blood vessels and V2 receptors in the kidney, according to the label.3 |
| FDA status | FDA-approved FDA-approved as DDAVP for diabetes insipidus and bedwetting1,2 FDA-approved. Drugs@FDA lists DDAVP, NDA 019955, with an original approval date of September 6, 1995. The cited label has no boxed warning.1,2 | FDA-approved FDA-approved as Vasostrict for vasodilatory shock3,4 FDA-approved. Drugs@FDA lists Vasostrict with an original approval date of April 17, 2014. The cited label has no boxed warning.3,4 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.5 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Desmopressin is not among them.5,6 | Not among the six peptides the policy lists.5 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not addressed in this profile’s sources. |
| Kinds of studies cited | Smaller controlled human trials
|
|
| Records collected | 25 ClinicalTrials.gov records and 25 PubMed records collected | 30 ClinicalTrials.gov records and 30 PubMed records collected |
| Area of study | ||
| Latest dated events |
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1DDAVP (desmopressin acetate) tablet · SPL version 7 · published 2025-12-10 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 2Drugs@FDA: DDAVP (desmopressin acetate), NDA 019955 · original approval September 6, 1995 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 3VASOSTRICT (vasopressin) injection · SPL version 49 · published 2026-05-18 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 4Drugs@FDA: VASOSTRICT (vasopressin), NDA 204485 · original approval April 17, 2014 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 5HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 6Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026